| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yu-Ju Shih, Ching-Hua Lin, Li-Shiu Cho. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006-2021. Medicine. vol 103. issue 51. 2024-12-20. PMID:39705447. |
the factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in taiwan, 2006-2021. |
2024-12-20 |
2024-12-23 |
Not clear |
| Yu-Ju Shih, Ching-Hua Lin, Li-Shiu Cho. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006-2021. Medicine. vol 103. issue 51. 2024-12-20. PMID:39705447. |
clozapine treatment continues to be recognized as the gold standard for managing treatment-resistant schizophrenia. |
2024-12-20 |
2024-12-23 |
Not clear |
| Yu-Ju Shih, Ching-Hua Lin, Li-Shiu Cho. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006-2021. Medicine. vol 103. issue 51. 2024-12-20. PMID:39705447. |
combining clozapine with other antipsychotics (i.e., clozapine polypharmacy) has emerged as an option for clozapine-resistant schizophrenia. |
2024-12-20 |
2024-12-23 |
Not clear |
| Yu-Ju Shih, Ching-Hua Lin, Li-Shiu Cho. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006-2021. Medicine. vol 103. issue 51. 2024-12-20. PMID:39705447. |
we aimed to investigate the factors associated with clozapine polypharmacy in schizophrenia patients discharged on clozapine from a public psychiatric hospital. |
2024-12-20 |
2024-12-23 |
Not clear |
| Yu-Ju Shih, Ching-Hua Lin, Li-Shiu Cho. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006-2021. Medicine. vol 103. issue 51. 2024-12-20. PMID:39705447. |
the analysis included patients with schizophrenia who were discharged between 2006 and 2021 and prescribed clozapine upon discharge. |
2024-12-20 |
2024-12-23 |
Not clear |
| Yu-Ju Shih, Ching-Hua Lin, Li-Shiu Cho. The factors associated with clozapine polypharmacy for schizophrenia patients discharged from a large public psychiatric hospital in Taiwan, 2006-2021. Medicine. vol 103. issue 51. 2024-12-20. PMID:39705447. |
a total of 1396 (42.7%) schizophrenia patients discharged on clozapine polypharmacy. |
2024-12-20 |
2024-12-23 |
Not clear |
| Toshihiro Sato, Takeshi Kawabata, Masaki Kumondai, Nagomi Hayashi, Hiroshi Komatsu, Yuki Kikuchi, Go Onoguchi, Yu Sato, Kei Nanatani, Masahiro Hiratsuka, Masamitsu Maekawa, Hiroaki Yamaguchi, Takaaki Abe, Hiroaki Tomita, Nariyasu Man. Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia. International journal of molecular sciences. vol 25. issue 23. 2024-12-17. PMID:39684938. |
effect of organic anion transporting polypeptide 1b1 on plasma concentration dynamics of clozapine in patients with treatment-resistant schizophrenia. |
2024-12-17 |
2024-12-21 |
Not clear |
| Toshihiro Sato, Takeshi Kawabata, Masaki Kumondai, Nagomi Hayashi, Hiroshi Komatsu, Yuki Kikuchi, Go Onoguchi, Yu Sato, Kei Nanatani, Masahiro Hiratsuka, Masamitsu Maekawa, Hiroaki Yamaguchi, Takaaki Abe, Hiroaki Tomita, Nariyasu Man. Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia. International journal of molecular sciences. vol 25. issue 23. 2024-12-17. PMID:39684938. |
the involvement of drug-metabolizing enzymes and transporters in plasma clozapine (clz) dynamics has not been well examined in japanese patients with treatment-resistant schizophrenia (trs). |
2024-12-17 |
2024-12-21 |
Not clear |
| Jonatan M Panula, Athanasios Gotsopoulos, Jussi Alho, Jaana Suvisaari, Maija Lindgren, Tuula Kieseppä, Tuukka T Rai. Multimodal prediction of the need of clozapine in treatment resistant schizophrenia; a pilot study in first-episode psychosis. Biomarkers in neuropsychiatry. vol 11. 2024-12-14. PMID:39669516. |
multimodal prediction of the need of clozapine in treatment resistant schizophrenia; a pilot study in first-episode psychosis. |
2024-12-14 |
2024-12-21 |
Not clear |
| Mohamed Adil Shah Khoodoruth, Tarteel Hussain, Sami Ouanes, Nuzhah Widaad Chut-Kai Khoodoruth, Adel Hmissi, Samuel L Lachica, Mustafa Nissar Bankur, Abdul Waheed Khan, Mohamad Samir Makki, Yasser Saeed Khan, James Currie, Majid Alabdullah, Farhan Mohamma. Peripheral inflammatory and metabolic markers as potential biomarkers in treatment-resistant schizophrenia: Insights from a Qatari Cohort. Psychiatry research. vol 344. 2024-12-07. PMID:39644591. |
linear regression analysis revealed that mlr and clozapine treatment were significantly correlated with the severity of schizophrenia symptoms. |
2024-12-07 |
2024-12-10 |
human |
| Yuqi Hu, Le Gao, Lingyue Zhou, Wenlong Liu, Cuiling Wei, Boyan Liu, Qi Sun, Wenxin Tian, Rachel Yui Ki Chu, Song Song, Franco Wing Tak Cheng, Joe Kwun Nam Chan, Amy Pui Pui Ng, Heidi Ka Ying Lo, Krystal Chi Kei Lee, Wing Chung Chang, William Chi Wai Wong, Esther Wai Yin Chan, Ian Chi Kei Wong, Yi Chai, Francisco Tsz Tsun La. Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study. PLoS medicine. vol 21. issue 12. 2024-12-05. PMID:39636825. |
rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: a population cohort study. |
2024-12-05 |
2024-12-08 |
Not clear |
| Xinyue Chen, Xinyan Wu, Wenjing Zhang, Kaike Liao, Rui Yu, Su Lui, Nian Li. Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. Journal of psychiatric research. vol 181. 2024-12-05. PMID:39637715. |
alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. |
2024-12-05 |
2024-12-08 |
Not clear |
| Xinyue Chen, Xinyan Wu, Wenjing Zhang, Kaike Liao, Rui Yu, Su Lui, Nian Li. Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. Journal of psychiatric research. vol 181. 2024-12-05. PMID:39637715. |
this study was devised to examine potential alterations in regional homogeneity (reho) that arise in schizophrenia patients with comorbid mets undergoing risperidone or clozapine treatment. |
2024-12-05 |
2024-12-08 |
Not clear |
| Xinyue Chen, Xinyan Wu, Wenjing Zhang, Kaike Liao, Rui Yu, Su Lui, Nian Li. Alterations in regional homogeneity in schizophrenia patients comorbid with metabolic syndrome treated with risperidone or clozapine. Journal of psychiatric research. vol 181. 2024-12-05. PMID:39637715. |
in total, 43 schizophrenia patients undergoing risperidone or clozapine treatment were enrolled in this study, of whom 20 had comorbid mets (sz-mets) while 23 did not (sz-nmets). |
2024-12-05 |
2024-12-08 |
Not clear |
| Tegen Williams, Emily Re. Lessons learnt in the end-of-life management of a hospice inpatient with advanced oropharyngeal cancer established on clozapine for treatment-resistant schizophrenia. BMJ case reports. vol 17. issue 12. 2024-12-04. PMID:39631905. |
lessons learnt in the end-of-life management of a hospice inpatient with advanced oropharyngeal cancer established on clozapine for treatment-resistant schizophrenia. |
2024-12-04 |
2024-12-07 |
Not clear |
| Kathleen Shangraw, Christian Schmutz, Tom Dowdle, Ryan Kelley, Caleb Porter, Merrick Reynolds, Zachary Schwartz, Olivia Sutton, Brent Kiou. Medical, Psychiatric, and Sociodemographic Predictors of Clozapine Initiation at an Academic Medical Center. Psychiatric research and clinical practice. vol 6. issue 3. 2024-11-21. PMID:39568504. |
this study aimed to identify factors affecting clozapine prescribing patterns among patients with treatment-resistant schizophrenia and schizoaffective disorder at an academic medical center. |
2024-11-21 |
2024-11-23 |
Not clear |
| Milo Wolfgang Pilgaard Kristensen, Bahast Biuk, Jimmi Nielsen, Kirsten Borup Bojesen, Mette Ødegaard Nielse. Glutamate, GABA and NAA in treatment-resistant schizophrenia: a systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders. Behavioural brain research. 2024-11-20. PMID:39566584. |
glutamate, gaba and naa in treatment-resistant schizophrenia: a systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders. |
2024-11-20 |
2024-11-23 |
Not clear |
| Milo Wolfgang Pilgaard Kristensen, Bahast Biuk, Jimmi Nielsen, Kirsten Borup Bojesen, Mette Ødegaard Nielse. Glutamate, GABA and NAA in treatment-resistant schizophrenia: a systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders. Behavioural brain research. 2024-11-20. PMID:39566584. |
treatment-resistance in patients with schizophrenia is a major obstacle for improving outcome in patients, especially in those not gaining from clozapine. |
2024-11-20 |
2024-11-23 |
Not clear |
| Milo Wolfgang Pilgaard Kristensen, Bahast Biuk, Jimmi Nielsen, Kirsten Borup Bojesen, Mette Ødegaard Nielse. Glutamate, GABA and NAA in treatment-resistant schizophrenia: a systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders. Behavioural brain research. 2024-11-20. PMID:39566584. |
to investigate these issues, we conducted a systematic review to evaluate the relationship between clozapine and in vivo measures of gamma-aminobutyric acid (gaba), glutamate (glu), and n-acetylaspartate (naa) brain levels in treatment- and ultra-treatment-resistant schizophrenia patients (trs and utrs). |
2024-11-20 |
2024-11-23 |
Not clear |
| Carlos De Las Cuevas, Emilio J Sanz, Jose de Leo. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety. Patient preference and adherence. vol 18. 2024-11-18. PMID:39553897. |
clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia in the united states (us). |
2024-11-18 |
2024-11-22 |
Not clear |